AbCellera Biologics UBS Global Biopharma Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
session at the UBS Biopharma Conference in London. I'm Alice Nettleton, one of the U.S. mid biotech analysts at UBS. Happy to introduce AbCellera. We have with us Carl Hansen, CEO. Thank you so much for joining us.
Thanks, Alice. It's a pleasure to be here.
So just to start then, maybe we can start off with a brief overview of AbCellera for those who might be newer to the story, and you can cover the exciting data that you had earlier this year, and then we can move to some Q&A.
Okay, great. I'll try to keep it short and punchy. AbCellera is a biotech company. We're located in Vancouver, British Columbia. We're about 14 years old. The company, through the first 10 years, we were very much focused on building best-in-world technology for solving difficult antibody discovery problems. And through that, we have put in place a platform that I think has conspicuous advantages in some important areas of antibody therapeutics, in particular targeting GPCRs and ion channels, and more recently, gaining a lot of traction in T-cell engagers. The first 10 years of the company, the business model was not the classic biotech. It was being hired guns for big pharma and biotech. So we had to cut our teeth solving the problems that others couldn't solve.
We had a big success with COVID-19, which resulted in a couple therapeutics that were brought to the market by Eli Lilly. Shortly after that, we went public, and through the result of that, we were able to bring in about $1.5 billion or so that funded a build-out of the platform to what is now a full end-to-end capability for antibody therapeutics. In 2023, we made the decision to switch gears in the business model and to pursue the more classic biotech approach of developing our own drugs. We have a large discovery pipeline, and over the last three years, we have been retooling the company to bring that into the clinic. Just this last year, we had our first two that went into the clinic. One was an OX40 Ligand half-life extended antibody that was a little bit opportunistic, that came from an earlier partnership.
It read out last week, it looks great, but we have decided to discontinue it just based on what has happened in the class. As you alluded to, the most exciting program is the lead asset, ABCL635, which is a first-in-class antibody antagonist of NK3R, a GPCR target, and it is being developed for the non-hormonal treatment of vasomotor symptoms, or hot flashes, associated with menopause or associated with hormone deprivation that is given in the treatment of breast cancer or prostate cancer.
We brought that into clinic about a year and a half ago, and in August, we had our phase II readout that just blew the doors off with efficacy that is roughly twice as good in reducing the frequency of hot flashes over the current market leaders, which are small molecule NK3R antagonists, and about four to five times as good in severity and with a clean safety profile. We think we have a very exciting opportunity to develop what will be a landmark in redefining medicine for the non-hormonal treatment of hot flashes, and we are currently preparing to scale up and put that into late-stage studies next year.
Great. Thank you for that overview.
Yeah. Maybe just digging a bit more into that four-week data update.
For people who are maybe less familiar with this indication, because it's quite a new area for investors, can you explain what are the key takeaways from that data, and what does it indicate about the potential differentiation? You've mentioned safety and efficacy.
Sure. Everyone is familiar with hot flashes. These are the most problematic symptom for women that are going through perimenopause and menopause. Essentially, they are episodes where you have a sudden flushing, increase in temperature. In high severity, you end up breaking a sweat, sometimes having to stop what you do, sometimes having to change clothing. It ends up being a very disruptive symptom for women at an important time in their lives, and it's a symptom that can last for a long time. The median time for hot flashes is about seven years. Recently, there's been a huge uptick in interest in treating hot flashes and in women's health, most notably from removal of the box warning on hormone products that happened just over a year ago, I believe.
The result has been a major change in expectation from women that they should be getting care and that they're expecting to be getting care. The opportunity that we're going after is not to replace hormone therapy, but rather that there's quite a large population of women that are either contraindicated for hormone therapy or that can't tolerate it, and there are very few good options. The most recent options are these small molecule NK3R antagonists, one that has been developed by Astellas and another by Bayer, LYNKUET and VEOZAH are their names. One has been on the market now about three years, one just a year. Those were the leaders that we were following.
In our readout, we showed that at four weeks, so a single dose and at four weeks, that in terms of reducing the frequency, the number of moderate to severe events, from a baseline of 10, we were able to get over an 80% total reduction and about a 50% reduction over placebo. There's quite a placebo response because of enrollment. That compares to 20% or 25% for the small molecule, so about twice the frequency efficacy. The other measure is severity. A measure of one means you had a hot flash, but it wasn't really a big deal. Two means you had to interrupt what you were doing, and three means that there's been perspiration and you have to change your clothes. It's like a very disruptive event.
From that perspective, we reduced it from 2.5, which is about half moderate, half severe, to one, which is a mild event. As I mentioned, that is about four to five times the effect that was seen with small molecules. We have done that with a safety profile that is clean. That is important because both small molecules have a warning for elevated liver enzymes, so potential liver injury, and both of those require liver monitoring as part of therapy. Our objective here is to have a product that is more convenient, once monthly dosing versus daily oral. It does not have a liver toxicity side effect and is safer, and importantly, that has much better efficacy. The efficacy that I mentioned is not just way better than the small molecules, it is on par or superior to trials that have been done with hormone therapy.
Really, the kind of clinical data that you very rarely see in a biotech, and to have that as the lead program on a GPCR target is just a terrific spot, so we are pretty pumped.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
